MedTrace Logo

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-04-14

No results posted yet for this study

Summary

This project aims to do a small sample exploratory study, to predict EGFR-TKI targeted therapy gefitinib' s efficacy in late stage lung adenocarcinoma patients (phase IIIB or IV), who have negative tissue EGFR gene mutation, positive plasma free nucleic acid EGFR gene.

Conditions

Sponsors & Collaborators

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • DAI X T, doctor · Department of Respiratory Diseases, Souty West Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-01-31
Completion
2018-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02738684 on ClinicalTrials.gov